Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.
| Revenue (Most Recent Fiscal Year) | $34.26M |
| Net Income (Most Recent Fiscal Year) | $-45.72M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.93 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.96 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -136.03% |
| Net Margin (Trailing 12 Months) | -133.45% |
| Return on Equity (Trailing 12 Months) | -122.60% |
| Return on Assets (Trailing 12 Months) | -48.98% |
| Current Ratio (Most Recent Fiscal Quarter) | 13.32 |
| Quick Ratio (Most Recent Fiscal Quarter) | 13.32 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.24 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.03 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.36 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.49 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 25.80M |
| Free Float | 24.77M |
| Market Capitalization | $203.33M |
| Average Volume (Last 20 Days) | 0.25M |
| Beta (Past 60 Months) | 1.09 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 37.99% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |